Alzheimer's Amyloid-Clearing Drugs May Not Help Patients and Could Increase Brain Risks

A major review of over 20,000 participants reveals that drugs designed to clear amyloid beta from the brain may not provide meaningful benefits to Alzheimer's patients. More concerning, these medications may increase the risk of brain swelling and bleeding, sometimes without obvious symptoms. This finding challenges previous assumptions about amyloid-targeting therapies as a promising treatment approach. The research suggests patients and healthcare providers should carefully weigh the potential risks against limited benefits when considering these treatments. The implications could reshape how neurologists approach Alzheimer's disease management and drug development strategies.